

## CURRICULUM VITAE

### BARRY D. BROOKS, M.D.

OFFICE: Medical City Dallas  
7777 Forest Lane, D-400  
Dallas, Texas 75230

HOME:

PHONE: 972-566-7790

PHONE:

BIRTH PLACE AND DATE:

FAMILY:

Children: Two

PREMEDICAL EDUCATION:

Texas Tech University, Lubbock, Texas  
B.A. in Chemistry, 1972 with honors

MEDICAL SCHOOL:

University of Texas Southwester Medical School,  
Dallas, Texas  
M.D., 1976 (AOA)

INTERNSHIP AND MEDICAL  
RESIDENCY:

Parkland Memorial Hospital and Dallas VA Hospital  
July 1, 1976 - June 30, 1979

FELLOWSHIP:

Parkland Memorial Hospital and Dallas VA Hospital  
Hematology/Oncology Fellowship  
July 1, 1980 - June 30, 1982

LICENSE:

Texas, E 6253, 1976

CERTIFICATION:

American Board of Internal Medicine, 1980  
American Board Medical Oncology, 1983

HONORARY SOCIETIES AND  
AWARDS:

Alpha Omega Alpha - Medical School Honorary

PROFESSIONAL ASSOCIATIONS:

American Society of Clinical Oncology  
Texas Medical Association  
Dallas County Medical Association  
Member, Texas Society of Medical Oncology  
American Society of Hematology  
Chairman, Texas Medical Association  
Committee on Cancer, 2008 - 2011

Texas Medical Association  
Committee on Science & Public Health,  
2008 - 2011

COMMITTEE MEMBERSHIPS:

Secretary of Medical Staff, Medical City Dallas, 1986  
President of Medical Staff, Medical City Dallas, 1989-  
1990  
Board of Trustees, Medical City Dallas, 1990 - 1992  
Medical City Executive Committee, 6 years  
Chairman, Department of Medicine, Medical City  
Dallas, 1993; 2004 - 2006  
Member, Privileges and Credentials Committee,  
Medical City Dallas, 1990 - 1994  
Board of Trustees, BLOODCARE (Dallas Area  
Bloodbank), 1994 - 1997  
Board of Trustees, CARTER BLOODCARE (Dallas-  
Fort Worth Bloodbank), 1998 - 2008

US ONCOLOGY ADMINISTRATIVE  
POSITIONS:

Chairman of Drug Contracting Committee,  
2004 - Present

Member, Pathway Task Force Committee  
(Supportive Care Subcommittee Chair),  
2005 - 2013

Pharmacy & Therapeutics Executive  
Committee Member, 2000 - Present

Medical Director and Chairman of US Oncology  
P&T Committee, 2011 - Present

PRIVATE PRACTICE:

Medical Oncology (50%), Hematology (50%)  
Dallas Diagnostic Association  
July 1982 - 1986

Texas Oncology, P.A.  
Group Practice  
Medical Oncology/Hematology  
1986 - Present

PUBLICATIONS:

“Therapeutic Plasma Exchange in Immune  
Hemolytic Anemias and immunologic  
Thrombocytopenic Purpura.” **PROGRESS IN  
CLINICAL AND BIOLOGICAL RESEARCH**,  
Volume 106. Page 317 - 330. Alan R. Liss, Inc.

“Therapeutic Plasmapheresis in Patients with  
Antibodies to High Frequency Red Cell Antigen.”  
E.A. Steane, R.G. Sheehan, **B.D. Brooks**, and

Eugene Frenkel. **PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH**, Volume 106. Page 347 - 354. 1982. Alan R. Liss, Inc.

“Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer.” S.E. Jones, R.G. Menzel, G.N. Peters, M.A. Estrick, **B.D. Brooks**, S.M. Knox, and P. McGuffey. **INVESTIGATIONAL NEW DRUGS 6**. pp 195 - 198, 1988. Kluwer

Academic Publishers- Printed in the Netherlands.

“Phase II Study of Mitoxantrone, Leucovorin, and Infusional Fluorouracil for Treatment of Metastatic Breast Cancer.” S.E. Jones, R.G. Menzel **B.D. Brooks**, M.A. Westrick, M.A. Allison, R.S. Paulson, K. Tilman, B. Rea. **JOURNAL OF CLINICAL ONCOLOGY**, Volume 9, Number 10. pp 1736 - 1739, 1991.

ABSTRACTS:

Rosenfeld C, Kerr R, **Brooks B**, White C, Savin M: “Adjuvant Chemotherapy Prior to ASCT for Breast Cancer: Less is More?” **American Society of Clinical Oncology**, Volume 19:232, 2000.

Goldman S, Stafford C, Weinthal J, Kerr R, White C, Savin M, **Brooks B**, Rosenfeld C, Lenarsky C: “Older Adolescents Vary Greatly from Children in Their route of Referral to the Pediatric Oncologist and National Trials.” **American Society of Clinical Oncology**, Volume 19:1766, 2000.

Jones S, **Brooks B**, et al: “Low Proliferative Rate of Invasive Node Negative Breast Cancer Predicts for a Favorable Outcome Without Adjuvant Chemotherapy.” **Proc Am Soc Clin Oncol** 18:70a, 1999 (Abstr 262).

Jones SE, Clark GM, Koleszar S, Ethington G, Menzel R, **Brooks B**, et al: “Five Year Results of Adjuvant Chemotherapy with Adriamycin and Cyclophosphamide (AC) in 450 Women with Invasive Node-Negative Breast Cancer with High S Phase Fraction (SPF).” **Proc Am Soc Clin Oncol** 19:13a, 2000 (Abstr 513).

Neubauer M, Gosse N, Verrilli D, **Brooks B**, et al: “Clinical pathways: are we there yet?” **Community Oncology** March 2013: 96-98.

Jain VK, Ogden J, Cox B, **Brooks B**, et al: "A Phase-II Trial of Infusional Etoposide, Vincristine and Doxorubicin with Bolus Cyclophosphamide (EPOCH) in Patients with Relapsed Hodgkins and Non-Hodgkins-Lymphomas." **Blood** 84:10, A643-A643. 1994.

Brow ME, Okon TA, George ER, Eagle D, Patt DA, Gould B, **Brooks B**, et al: "Thoughts and recommendations on cancer care site of service." **Community Oncology** 9, no. 12(2012): 382-388.

Hoverman JR, Sheth S, Clayton M, Neubauer M, **Brooks B**, et al: "Pemetrexed/cisplatin (pem/cis) Vs. Pemetrexed/carboplatin (pem/carbo) in Non-squamous, Non-small Cell Lung Cancer (nslc): A Retrospective Comparison Using A Large Electronic Database." **J Thor Onc**, Vol. 7, no. 9, pp. S273-S273, 2012.

Patt DA, Espirito JL, Turnwald B, Hoverman J R, Neubauer MA, Cartright TH, Busby LT, **Brooks B**, et al: "Changes in adjuvant breast cancer chemotherapy regimen selection over time in the community." **J Clin Onc**, vol. 30, no. 15 (2012).

**Brooks B**: "Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer. **Inv New Drugs**, September 1988. Vol. 6(3), pp 195-198.

Kolodziej M, Hoverman JR, Garey JS, Espirito J, Sheth S, Ginsburg A, Neubauer MA, Patt D, **Brooks B**, et al: "Benchmarks for Value in Cancer Care: An Analysis of a Large Commercial Population." **J Oncol Pract**, September 2011, vol. 7 no. 5, 301-306.

#### CURRENT RESEARCH:

Principal Investigator (TOPA) "A Randomized, Open-Label, Phase III Trial of Decitabine (5-AZA-2'-Deoxycytidine) Versus Supportive Care in Adults With Advanced-Stage Myelodysplastic Syndrome." - Closed 2002.

Principal Investigator (TOPA) "A Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Safety And Efficacy Of Thalidomide (Thalomid) For The Treatment Of Anemia In Red Blood Cell Transfusion Dependent Patients With Myelodysplastic Syndromes." - Closed 2002.

Principal Investigator “A Multi-Cancer, Randomized Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes.” - USON Trial 04109. Closed April 2007.